What You Should Know:
- Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK's national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus.
- Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Analysis: Applying AI in the Fight Against The Coronavirus
Drug discovery is a notoriously long, complex and expensive process requiring the concerted efforts of the world’s brightest minds. The complexity in understanding human physiology and molecular mechanisms is increasing with every new research paper published and for every new compound tested. As the world is facing a new challenge in trying to both adapt to and defend itself against the coronavirus, artificial intelligence is offering new hope that a cure might be developed faster than ever
Read More
COVID-19 Treatment and Vaccine Tracker Identifies New Treatments & Vaccines in Development
What You Should Know:
- The Milken Institute launched an effort to track and disseminate accurate information about COVID-19 treatments and vaccines in development.
- Since launch, more than two dozen new candidates have been identified, with some progressing toward clinical trials.
The Milken Institute COVID-19 Treatment and Vaccine Tracker has
identified 16 new treatments in the pipeline along with nine new vaccine candidates
since
Read More
AstraZeneca Selects BrightInsight’s IoT Platform to Focus on Chronic Disease Management
What You Should Know:
- AstraZeneca selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment
- Digital health represents a major opportunity to alleviate some of the biggest concerns in healthcare today—many of which are being amplified due to COVID 19—including the length and cost of clinical trials, better remote testing, and tracking of patients, access to data and delivery of care.
- AstraZeneca and others are
Read More
Wolters Kluwer, SAS Integrate to Power Real-World Evidence (RWE) Analytics
- SAS to leverage Wolters Kluwer’s Health Language portfolio of data quality solutions to power real-world evidence (RWE) analytics within SAS Health.
- Through a disease-centric approach, Health Language will enable SAS Health’s clients to more effectively manage reference data, such as ICD-10, CPT® and SNOMED CT, establish relationships between clinical and claims data and extract value from unstructured text within the medical record–providing a comprehensive view of a patient’s clinical
Read More
IBM Watson Health Launches Data-Driven Tool to Optimize Clinical Trials
- Today, IBM announced its data-driven tool, IBM Study Advance that optimizes clinical trial protocol design by providing access to real-world patient population data, a collaborative workplace and standardizing protocol template guidance.
- IBM Study Advance’s collaborative workspace is designed to allow near real-time collaboration with study design team members who can manage and assign the team to specific sections of the protocol.
IBM Watson
Health today unveiled its newest
Read More
LexaGene Launches Genetic Analyzer for Detection of Pathogens like Coronavirus
- LexaGene has created a genetic analyzer that can identify specific bacteria and viruses as well as any antibiotic/antimicrobial resistance that they have, within just one hour.
- The device does this completely automatically, without the need for trained lab technicians, by amplifying the genetic material in the sample to identify it, rather than waiting for a culture which can take several days.
LexaGene Holdings, Inc., a biotechnology company that develops genetic analyzers
Read More
Verana Health Acquires PYAA Analytics; Raises $100M to Expand Real World Data Insights
- Verana Health, a health tech company (in the real-world evidence and clinical trials space) is announcing a $100M funding round today — led by GV (with participation by Bain, Define, Brook Byers and others).
- Additionally, they acquired Knoxville-based PYAA analytics, a company spun out of Oak Ridge National Laboratory to leverage the PYAA team’s capabilities to integrate imaging, genomic, and claims data sources into the existing data platform and link these data with the EHR data
Read More
Notable Launches Observational Clinical Trial for Patients with Blood Cancer
- Notable launches The ANSWer Study, it's new observational clinical trial for patients with blood cancer and is currently enrolling patients.- The primary assessment is to establish a tumor registry with annotated clinical outcomes.Notable, a San Francisco, CA-based company redefining cancer treatment with a clinically validated platform that rapidly advances drug development, is currently enrolling patients in its new observational clinical trial. The clinical trial will take place at
Read More
CVS: 4 Approaches to Reduce The Cost Impact of Gene Therapies
- While the life-changing and life-saving potential of gene therapies is tremendously exciting, finding ways to pay for these treatments is a significant challenge for families and payors.- With prices for a single treatment as high as $2 million, many employers are struggling to find ways to offer coverage without bankrupting their health plans, or even their companies.- Newly released CVS Health white paper outlines four key approaches that health plans and employers can utilize to reduce the
Read More
